VivoSeq
Infectious Disease

Complicated Appendicitis

7

Pipeline Programs

4

Active Trials

7

Companies Involved

Complicated Appendicitis is an early-stage landscape with 7 programs across 7 companies. The most active players are Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Melinta Therapeutics, Inc., Bayer. 4 therapies are approved.

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

83/100

Attrition Rate

8/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Trial Status

12

clinical trials

Completed5 · 42%
Unknown status2 · 17%
Not yet recruiting2 · 17%
Terminated1 · 8%
Enrolling by invitation1 · 8%
Recruiting1 · 8%

Trial Activity

12 trials

Antibiotics vs. Placebo in Acute Uncomplicated Appendicitis
Enrolling by invitation·TTurku University Hospital·N/A·NCT03234296·147 enrolled
Optimal Care of Complicated Appendicitis
Completed·UUniversity of Michigan·Phase 4·NCT03159754·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)